Drug
Crizotinib
Data on this page refer exclusively to patients treated with
Crizotinib combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
Multi-target TKI group page.
Drug Profile
| Therapeutic Class | Targeted Therapy |
| Drug Class | Tyrosine Kinase Inhibitors (TKIs) |
| Group | Multi-target TKI |
| Mechanism of Action | ALK/ROS1/MET inhibitor |
| Half-life | 42 h |
Location
Treated site
